Immunotherapy targeting immune checkpoints is an emerging research area in cancer treatment, and the study results indicated that the ZWINT gene can be used as a predictor of immunotherapy response to a certain extent (Supplementary Figure 9). The gene discussed is ZWINT; the disease is cancer.